Olema Oncology granted Jason V. O'Byrne, its new chief financial officer, stock options to purchase 650,000 shares of the company's common stock as an employment inducement award. The grant, effective 1 September 2026, has an exercise price of $10.56 per share, matching Nasdaq's last reported sale price on that date. The options vest over four years, with 25% vesting on 11 August 2027 and the remainder vesting in 36 equal monthly instalments over the following three years, subject to continuous employment. O'Byrne's appointment as CFO became effective 11 August 2026. The award was approved by Olema's Compensation Committee and granted under the company's 2022 Inducement Plan. Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer.

Olema Pharmaceuticals grants inducement stock options to newly appointed CFO Jason V. O'Byrne. Posted: 1 day, 9 hours ago / Sept. 2, 2026 8:40 p.m. UTC Olema Pharmaceuticals appointed Jason V. O'Byrne as CFO, granting him 650,000 stock options effective September 1, 2026. Quiver AI summary. Olema Pharmaceuticals, Inc. has announced the appointment of Jason V. O'Byrne as Chief Financial Officer, effective August 11, 2026. To incentivize his role, the company granted him an employment inducement award that includes stock options to purchase 650,000 shares at an exercise price of $10.56 per share, based on the latest Nasdaq reporting. The stock options will vest over four years, with an initial 25 percent vesting on August 11, 2027, followed by monthly vesting. This grant aligns with Nasdaq regulations and is part of Olema's 2022 Inducement Plan. Olema is focused on developing innovative treatments for breast cancer, including the lead candidate palazestrant, currently in Phase 3 trials, and OP-3136, which is in Phase 1 trials. The company operates out of San Francisco and Cambridge, Massachusetts. Potential positives. * Olema Pharmaceuticals appointed Jason V. O'Byrne as Chief Financial Officer, indicating a strategic move to strengthen the company's financial leadership. * The company granted an employment inducement award of 650,000 stock options to Mr. O'Byrne, demonstrating confidence in his capabilities and aligning his interests with shareholders. * The stock options are set at an exercise price equal to the last reported sale price, encouraging performance that aligns with market expectations. * Olema's ongoing commitment to developing innovative therapies for breast cancer, including their lead product candidate, palazestrant, underlines the company's focus on advancing significant medical solutions. Potential negatives. * Granting a significant stock option package (650,000 shares) to the new CFO may raise concerns among investors regarding the company's compensation practices, especially at a time when the company is still in the clinical stage and may not yet be financially stable. * The substantial vesting period for the stock options (four years) could be viewed negatively, as it may imply the need for long-term incentives to retain leadership amidst ongoing challenges in clinical trials and commercialization efforts. * The mention of the employment inducement award might distract from Olema's clinical updates and progress on drug development, potentially raising concerns about prioritization and resource allocation within the company. Faq. Who is Olema Pharmaceuticals? Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and beyond. What recent appointment did Olema announce? Olema announced the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026. What is the stock option grant for Jason O'Byrne? The stock option grant consists of 650,000 shares with an exercise price of $10.56 per share. How does the stock option vest? The stock options vest over four years, with 25% vesting on August 11, 2027, and the remainder in monthly installments. What are Olema's lead product candidates? Olema's lead product candidates include palazestrant (OP-1250) and OP-3136, targeting endocrine-driven cancers. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here. EARLY ACCESS Receive OLMA Data Alerts Real-time alerts on filings, insider trades, and market signals - before everyone else. $OLMA insider trading activity. $OLMA insiders have traded $OLMA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales. * SHAWNTE MITCHELL (CHIEF LEGAL OFFICER) has made 0 purchases and 2 sales selling 25,000 shares for an estimated $606,352. * CYRUS HARMON has made 0 purchases and 2 sales selling 25,000 shares for an estimated $291,162. To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint. $OLMA hedge fund activity. We have seen 94 institutional investors add shares of $OLMA stock to their portfolio, and 131 decrease their positions in their most recent quarter. Here are some of the largest recent moves: * RA CAPITAL MANAGEMENT, L.P. removed 2,600,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $32,526,000 * JENNISON ASSOCIATES LLC removed 1,822,123 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,794,758 * FMR LLC added 1,756,217 shares (+16.9%) to their portfolio in Q2 2026, for an estimated $21,970,274 * CORMORANT ASSET MANAGEMENT, LP removed 1,750,000 shares (-44.9%) from their portfolio in Q2 2026, for an estimated $21,892,500 * POLAR CAPITAL HOLDINGS PLC removed 1,602,970 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $20,053,154 * DEEP TRACK CAPITAL, LP added 1,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $18,765,000 * FRANKLIN RESOURCES INC added 1,130,629 shares (+92.8%) to their portfolio in Q2 2026, for an estimated $14,144,168 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint. $OLMA price targets. Multiple analysts have issued price targets for $OLMA recently. We have seen 6 analysts offer price targets for $OLMA in the last 6 months, with a median target of $39.0. Here are some recent targets: * Brad Canino from Guggenheim set a target price of $35.0 on 05/13/2026 * Dennis Ding from Jefferies set a target price of $40.0 on 03/19/2026 * Richard Law from Goldman Sachs set a target price of $27.0 on 03/18/2026 * Anupam Rama from JP Morgan set a target price of $58.0 on 03/18/2026 * Yigal Nochomovitz from Citigroup set a target price of $62.0 on 03/17/2026 * Emily Bodnar from HC Wainwright & Co. set a target price of $38.0 on 03/09/2026 Full release. SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O'Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company's common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 1, 2026. The award was approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan. The stock options vest over four years, with 25 percent vesting on August 11, 2027 and the remainder vesting in 36 equal monthly installments over the following three years, subject to continuous employment as of such vesting dates. Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com. Media and Investor Relations Contact Courtney O'Konek Vice President, Corporate Communications Olema Oncology [email protected]